Morgan Stanley analyst Mark Purcell lowered the firm’s price target on Novartis to CHF 93 from CHF 94 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis call volume above normal and directionally bullish
- B. Riley biotechnology analysts to hold an analyst/industry conference call
- Novartis maintains FY23 group guidance, mid-term outlook
- Novartis to appeal to uphold validity of Entresto combination patent
- Novartis weakness on Entresto patent ruling ‘seems overdone,’ says JPMorgan